Launched in 1982 with a single product, Pharmadass (through subsidiary HealthAid) sells more than 450 products: vitamins and minerals, beauty care items, weight-loss formulas, and aromatherapy oils. It also sells anti-smoking products, herbal cigarettes, anti-snoring spray, and such supplements as fish oils and bee products. Specialty lines focus on such areas as mood enhancement, women's health, the immune system, and vitality. Pharmadass products are found in about 4,000 pharmacies and health food stores in the UK and in 30 countries worldwide.

Eisai develops, manufactures, and distributes prescription pharmaceuticals, primarily in North America and Japan. Prescription drug sales account for a majority of the company's revenues and are led by Aricept, which treats Alzheimer's disease. Other drugs include Myonal, a muscle relaxant, and AcipHex, an acid reflux and ulcer treatment (sold as Pariet in Japan and Europe). Development programs target neurology, oncology, vascular, and immunological ailments. In Japan the company distributes generic and non-prescription drugs and consumer health products. Eisai also makes food additives and chemicals, in addition to drug manufacturing equipment and systems.

GE Healthcare Medical Diagnostics helps your doctor to see right through you. The division, formerly Amersham plc, is one of the world's top producers of contrast-imaging agents and nuclear medicine agents used to enhance image quality in X-ray, magnetic resonance imaging, and ultrasound procedures. General Electric formed the division when it acquired Amersham and placed under its GE Healthcare umbrella. The former Amersham bioscience operations, which makes purification systems that allow for the development of more effective drugs through protein analysis, DNA sequencing, and genetic variation, is part of the GE Healthcare Life Sciences division.

Rules-Based Medicine, Inc. company was founded in 1998 and is headquartered in Austin, Texas. Rules-Based Medicine, Inc., a life sciences company, focuses on the development and commercialization of molecular diagnostic tests based on novel biomarker patterns primarily for the psychiatric market. It develops molecular diagnostic tests using its proprietary multi-analyte profiling, or MAP, technology that helps to screen large sets of well-characterized clinical samples from both diseased and non-diseased populations against a menu of biomarker immunoassays. The company’s pharmaceutical services consist of MAP testing services, custom MAP services, multiplexed immunoassay kits, and TruCulture and other co-culture services. It markets its laboratory testing products and services primarily to drug development professionals at pharmaceutical and biotechnology companies.

Novartis Corporation has what the doctor ordered. As the North American headquarters of Switzerland-based Novartis AG, the unit handles administration, sales, and marketing for a vast product line of prescription drugs, consumer health products, vaccines, and veterinary products. But wait, there is more! Novartis Corporation also oversees the Novartis Institutes for Biomedical Research, which is headquartered in the US. Novartis Corporation headlines dozens of US business units including CIBA Vision, Novartis Pharmaceuticals, and the US operations of its Sandoz generics business.

Cyclacel Pharmaceuticals, Inc. company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer; Seliciclib (CYC202), a CDK (cyclin dependent kinase) inhibitor, which is in phase II studies for the treatment of lung cancer and nasopharyngeal cancer; and CYC116, an Aurora kinase and VEGFR2 inhibitor that is in phase I studies for patients with solid tumors. The company, through its subsidiary, ALIGN Pharmaceuticals, LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States. It focuses on building a diversified biopharmaceutical business focused in hematology, oncology, and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

RegeneRx Biopharmaceuticals was founded in 1982 and is headquartered in Rockville, Maryland. RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of novel molecules to promote tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tb4), a 43 amino acid peptide. Its product candidates in clinical development include RGN-137, a topically applied gel for chronic dermal wounds; RGN-259, a sterile topical eye drop for ophthalmic wounds; and RGN-352, a parenteral formulation for the treatment of patients with an acute myocardial infarction, or heart attack. Its pre-clinical development product includes RGN-457, an inhaled formulation of Tb4 targeting cystic fibrosis and other pulmonary diseases. The company has a strategic partnership with Defiante Farmaceutica L.d.a. for the development and marketing of RGN-137, and certain indications relating to RGN-352 primarily in Europe.

Novartis UK, pharmaceutical manufacturing isn't just a business, it's an art. Novartis UK is the British affiliate of Swiss-based Novartis AG, its operations include Novartis Pharmaceuticals UK, the prescription drug production arm that makes such products as tumor inhibitor Glivec and pain reliever Voltaren. Its Vaccine and Diagnostics division operates an influenza vaccine manufacturing facility. The company's Consumer Health division develops and manufactures such OTC products as Savlon antiseptic and Otrivin decongestant. Consumer Health also manufactures and markets drugs for companion animals and livestock, and includes contact lens maker CIBA Vision (UK).

Zogenix is intent on alleviating that nasty migraine of yours. The biopharmaceutical company is focused on developing and commercializing central nervous system (CNS) and therapeutic pain medications. The company received FDA approval for its Sumavel DosePro (sumatriptan) candidate in 2009. The drug, previously known as Intraject, utilizes the company's needle-free drug delivery technology and administers sumatriptan for the relief of acute migraines and cluster headaches. Its other late-stage candidate, ZX002, is an oral controlled release formulation of hydrocodone, used for the treatment of chronic pain. Biotechnology veteran Cam Garner founded Zogenix in 2006.

Neptune Technologies & Bioressources harvests krill (tiny deepwater crustaceans that resemble shrimp) from the ocean and processes it into value-added bioactive ingredients including polyunsaturated fatty acids and antioxidants. These 'Neptune Krill Oil'-based products are used in cosmetics and nutritional supplements as an alternative to vegetable oils. The company's Neptune Krill Aquatein is a marine protein concentrate also used in nutritional supplements. Neptune Technologies intends to penetrate the biopharmaceutical industry, using its marine oil extracts as a medicinal base.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.